Abstract Background Hepatitis B virus (HBV) infection disproportionately affects people with HIV (PWH) due to shared transmission routes. Data from the 1990s-2010s showed that 5-10% of PWH had chronic HBV in the United States. In the past decade, broader use of HBV-active and inactive antiretroviral therapy (ART), improved HBV vaccinations, and increasing intravenous drug use (IDU) may have changed the landscape of HBV infection in PWH and people without HIV (PWoH), but this has not been well studied. Methods This study aimed to describe the prevalence of HIV/HBV coinfection among participants enrolled across 13 U.S. MACS/WIHS Combined Cohort Study (MWCCS) clinical research sites. Between 11/2020 and 3/2024, participants underwent serologic testing for HBV. We defined a positive result for HBsAg (surface antigen) as a current infection; negative HBsAg and positive anti-HBV core antibody (anti-HBc) as past infection; and both negative HBsAg and anti-HBc as never infection. We used the Chi-squared or Fisher’s exact test to compare categorical variables and the Kruskal-Wallis test for continuous variables among three HBV serogroups.Figure 1:Age group distribution of all participants stratified by Hepatitis B (HBV) serologic status Results Among 2130 participants, HIV seropositivity was associated with higher rates of current (PWH 3.1% vs. PWoH 1.7%) and prior HBV infection (PWH 28% vs. PWoH 23%, P=0.006) (Table 1). Current HBV infection was more common in men (3.9% in males and 1.7% in females) and those in the 40-59 age group (3.8% in the 40-49 age group and 2.8% in the 50-59 group) (Figure 1). Prior HBV infection was associated with higher rates of substance use, especially injection drug use, and having been infected with hepatitis C (Table 1B). Among PWH, current HBV infection was more common in men than women (4.7% vs. 1.7%, Table 2A). HIV suppression, CD4 count and nadir, and HBV-active ART use were similar among PWH across HBV categories (Table 2B). In PWH who never had HBV infection, 39% did not have immunity against HBV. Conclusion The prevalence of HIV/HBV coinfection in this selected group of the MWCCS cohort is 3.1%, lower than previously reported in the 1990s-2010s. Male participants in the age group of 40-59 years are at higher risk for current HBV infection. Our study also highlights the need to screen for HBV immunity in people who never had HBV but are at risk for HBV infection. Disclosures Jennifer C. Price, MD, PhD, AbbVie: Grant/Research Support|Gilead: Grant/Research Support|VIR: Grant/Research Support Maria L. Alcaide, MD, Gilead: Advisor/Consultant Valentina Stosor, MD, American Physician Institute: Honoraria|CDC: Grant/Research Support Bernard JC Macatangay, MD, Merck: Grant/Research Support
Guevara et al. (Thu,) studied this question.